Navigation Links
Cystic Fibrosis foundation lays out new treatment guidelines
Date:11/15/2007

New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.

The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the second issue for November of the American Thoracic Societys American Journal of Respiratory and Critical Care Medicine.

CF is a complex genetic disease affecting the lungs and other organs, and is characterized by an unusually thick, sticky mucus that renders CF victims virtually incapable of fending off infections and pathogens. CF is always fatal, but thanks to advances in treatment in the last 60 years, life expectancy has increased from just a few years to 36 years. Lung disease accounts for 85 percent of the mortality among CF patients.

"Physicians treating patients with CF are faced with a growing number of treatment options" wrote lead author of the guidelines, Patrick A. Flume, M.D. "We are hopeful that clinicians will find these recommendations to be useful in their care of patients with CF."

The pulmonary guidelines committee assessed the clinical efficacy and safety of the use of aerosolized antibiotics, recombinant human DNase (dornase alfa), hypertonic saline inhalation, anti-inflammatory agents, macrolide antibiotics, the use of bronchodilators and N-acetylcysteine. They analyzed the clinical results with regard to the number of studies, strength of the study designs and the quality and consistency of results to make their final recommendations. Because of the general dearth of studies on treatments in children under the age of six, the committee restricted their recommendations to CF patients six years of age and older.

The treatments with the strongest, most consistent results yielding an "A"-grade positive recommendation were:

  • Inhaled tobramycin, an antibiotic, to suppress chron
    '/>"/>

Contact: Suzy Martin
smartin@thoracic.org
212-315-8631
American Thoracic Society
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
3. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
4. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
5. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
6. Liver fibrosis will be treated by a potential target
7. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
8. MRI predicts liver fibrosis, study says
9. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
10. National Patient Safety Foundation Partners with Vocera Communications
11. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... July 31, 2014 The VitalSleep anti snoring device ... forward to help open a snorers airway to quiet snoring. ... helped her relationship with her husband by allowing them to ... years old. My snoring began about 15 years ago and I ... children could not sleep and had to head downstairs for any ...
(Date:7/31/2014)... 31, 2014 The controversy surrounding ... LLP notes that Johnson & Johnson’s Ethicon, Inc. ... remove its power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) from ... the company said it decided to do so ... devices remain uncertain.* , “In light of mounting ...
(Date:7/31/2014)... July 31, 2014 Infection prevention and ... and maintenance of products in the pharma, medical device, ... by using various products and equipment types; the two ... various materials and products. , The world market ... forecast to post a CAGR of about 7.5% through ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has shown an increased risk of spreading undetected cancers in ... market. In a letter that was to be sent ... that its laparoscopic power morcellators be returned to the company, ... of new morcellators had been suspended in April after the ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 2Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 3
... associated with enhanced communications between families and caregivers, ... for children dying from cancer, according to study ... Hospital Boston. , Published in the April 1 ... study,s findings also suggest that the parents were ...
... that Planned Parenthood affiliates in Florida,have been falsifying ... show,that what happened in California is not an ... Life League,renewed its call for a national investigation ... Florida allege falsified annual,reports., "It,s outrageous that ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... and TAMPA, Fla., March 28 ... LLC (myMatrixx) are pleased to,announce an ... bill review program and myMatrixx,s pharmacy ... first fully-integrated and automated,program between a ...
... Darwin,Professional Underwriters, Inc. (Darwin) (NYSE: DR ... Romano, who served as its senior vice ... Romano has become,associated with a competing professional ... http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ), The company ...
... March 28 Conseco, Inc. (NYSE:,CNO) announced today that ... for,the year ended December 31, 2007 with the Securities ... common stock for 2007 was $194.0,million, compared to the ... 2008 preliminary results. The reported net loss applicable to,common ...
Cached Medicine News:Health News:Study finds improvement in the care of children with cancer at the end of life 2Health News:Study finds improvement in the care of children with cancer at the end of life 3Health News:American Life League: Planned Parenthood Scandals 'Widespread' 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Conseco Files 10-K and Sets Earnings Release Date 2
(Date:7/31/2014)... NEW YORK und KISSING, Deutschland, ... ein Hersteller und Distributor eines computerunterstützten („robotischen") ... Nachum (Homi) Shamir , ein weltweit ... seines Leitungs- und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener ...
(Date:7/31/2014)... July 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... the second quarter 2014, on Thursday, August 7, 2014 ... a live webcast and conference call at 8:00 a.m. ... management will host the call and webcast to discuss ... may be accessed by calling (800) 708-4540 (domestic) or ...
(Date:7/31/2014)... 2014 Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" ... premium branded consumer products, including commercially cultivated Cordyceps Militaris ... announced the signing of its first distributor for its ... Hubei Province located ... . The contract with the ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: ... it has completed the previously announced acquisition of BMP ... stockholders held today, BMP Sunstone stockholders approved the adoption ... Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, ...
... Conn., Feb. 24, 2011 Mira Dx announced today that ... acceptance of a pivotal breast cancer study in the January ... BRCA1 coding sequence mutations are associated with breast ... less than 5% of breast cancer risk. The research identified ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2
HbA1c / HbCalibrator...
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
... Abnormal Control Plasmas for ... D-dimer and Free Protein ... For use with STA© ... D-DI (#0515) andSTA© LIATEST© ...
CRP Full Range (0.1-160mg/l)...
Medicine Products: